浅静脉血栓形成:综述
该综述总结浅静脉血栓(SuVT)年发病率64–131/10万人年,约10%进展为深静脉血栓或肺栓塞。危险因素与深静脉血栓相似,包括妊娠、静脉曲张、活动性癌症;上肢SuVT主要由留置静脉导管引起。D-二聚体敏感性约48%–74.3%,不能可靠排除SuVT。约25%下肢SuVT伴发深静脉血栓。治疗可包括弹力压缩袜和非甾体抗炎药;对于长度至少5 cm或保守治疗数天后症状持续或加重者,抗凝用磺达肝癸钠2.5 mg,替代方案包括利伐沙班10 mg每日一次和低分子肝素(如依诺肝素40 mg每日一次);距深静脉3 cm以内的SuVT应使用治疗剂量抗凝(如直接口服抗凝药)。
要点
- 约25%的下肢浅静脉血栓患者同时存在深静脉血栓,评估时需警惕。
- D-二聚体敏感性约48%–74.3%,不能可靠排除浅静脉血栓。
- 浅静脉血栓距深静脉3 cm以内者,应使用治疗剂量抗凝(如直接口服抗凝药)。
- 浅静脉血栓长度至少5 cm或保守治疗数天后症状持续或加重者,抗凝用磺达肝癸钠2.5 mg。
- 替代抗凝方案包括利伐沙班10 mg每日一次和低分子肝素(如依诺肝素40 mg每日一次),可能减少后续静脉血栓栓塞事件。
适用人群与场景
- 下肢或上肢浅静脉血栓患者,典型表现为皮下有压痛、红色、可触及的条索。
- 下肢SuVT临床危险因素与深静脉血栓和肺栓塞相似,包括妊娠、静脉曲张和活动性癌症。
- 上肢SuVT主要由留置静脉导管引起。
诊断标准与关键阈值
- 无典型症状和体征者,超声可确定血栓的存在和范围。
- D-二聚体检测敏感性约48%–74.3%,不能可靠排除SuVT。
- 约25%下肢SuVT患者就诊时伴发深静脉血栓。
处置流程与药物剂量
- 治疗可包括弹力压缩袜和非甾体抗炎药。
- 对于长度至少5 cm的SuVT,或保守治疗数天后症状持续或加重者,抗凝用磺达肝癸钠2.5 mg。
- 替代抗凝治疗包括利伐沙班10 mg每日一次和低分子肝素(如依诺肝素40 mg每日一次),可能减少后续静脉血栓栓塞事件。
- 位于距深静脉3 cm以内的SuVT,应使用治疗剂量抗凝,如直接口服抗凝药。
红旗征与不能漏的情况
- 约10%的SuVT患者进展为深静脉血栓或肺栓塞。
- 约25%的下肢SuVT患者伴发深静脉血栓。
- 距深静脉3 cm以内的SuVT应使用治疗剂量抗凝(如直接口服抗凝药)。
研究设计与关键结果
- 综述汇总:SuVT估计年发病率为64–131/10万人年。
- 女性SuVT发病率高于男性(女性78–167/10万人年 vs 男性49–116/10万人年)。
- 约10%的SuVT患者进展为深静脉血栓或肺栓塞。
- 约25%的下肢SuVT患者伴发深静脉血栓。
- D-二聚体检测敏感性约48%–74.3%,不能可靠排除SuVT。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对疑似SuVT患者,不应仅凭D-二聚体阴性排除诊断(敏感性约48%–74.3%)。
- 无典型症状和体征者,可用超声确定血栓存在和范围。
- 对下肢SuVT,需评估是否伴发深静脉血栓(约25%伴发)。
- 长度至少5 cm或保守治疗数天后症状持续或加重者,抗凝用磺达肝癸钠2.5 mg;替代方案为利伐沙班10 mg每日一次或低分子肝素(如依诺肝素40 mg每日一次)。
- 距深静脉3 cm以内的SuVT,应使用治疗剂量抗凝(如直接口服抗凝药)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Superficial vein thrombosis (SuVT) is characterized by thrombus in the superficial veins, typically in the lower or upper extremities, and has an estimated annual incidence of 64 to 131 per 100 000 person-years. Approximately 10% of patients with SuVT progress to deep vein thrombosis (DVT) or pulmonary embolism (PE).
OBSERVATIONS: Endothelial injury (caused by infection or intravenous devices), venous stasis (such as from chronic venous insufficiency or prolonged immobility), and hypercoagulability (due to cancer or pregnancy) are pathophysiologic factors associated with SuVT. Clinical risk factors for lower extremity SuVT are similar to those of DVT and PE and include pregnancy, varicose veins, and active cancer. The incidence of SuVT is greater in females than males (78-167 compared with 49-116 per 100 000 person-years). In contrast with lower extremity SuVT, upper extremity SuVT is primarily caused by indwelling intravenous catheters. Patients typically present with a tender, red, palpable cord under the skin in the upper or lower extremity. D-dimer testing has a sensitivity of approximately 48% to 74.3% and, therefore, is not reliable for excluding SuVT. Approximately 25% of patients with lower extremity SuVT present with concomitant DVT, likely because risk factors for SuVT and DVT are similar and because SuVT can extend into deep veins. In people without classic symptoms and signs of SuVT, ultrasonography can establish the presence and extent of the thrombus. Management may include elastic compression stockings and nonsteroidal anti-inflammatory drugs. For patients with SuVTs that are at least 5 cm long or those with persistent or worsening symptoms despite several days of conservative therapy, treatment includes anticoagulation with fondaparinux 2.5 mg. Alternative anticoagulation treatment includes rivaroxaban 10 mg once daily and low-molecular-weight heparins (eg, enoxaparin 40 mg once daily), which may reduce subsequent venous thromboembolic events. SuVT located within 3 cm of a deep vein should be treated with therapeutic doses of anticoagulation such as direct oral anticoagulants.
CONCLUSIONS AND RELEVANCE: SuVT typically presents as a tender, painful, palpable cord under the skin. Management may include elastic compression stockings, nonsteroidal anti-inflammatory drugs, and systemic anticoagulation with fondaparinux 2.5 mg or rivaroxaban 10 mg. SuVTs within 3 cm of a deep vein should be treated with therapeutic dose anticoagulation.
参考来源
- Piazza G, Krishnathasan D, Hamade N, et al. Superficial Vein Thrombosis: A Review. JAMA. 2025. PMID: 40952730. doi:10.1001/jama.2025.15222
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。